Overview

Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment.
Phase:
PHASE2
Details
Lead Sponsor:
Indivior Inc.